Botox injections are one of the fastest ways to eliminate wrinkles and give the face a more youthful appearance. In fact, it has become the most common non-invasive cosmetic procedure in the world, according to the American Society of Plastic Surgeons.
However, when Botox is overused, the result is a “paralyzed” face that can barely move. This happens because Botox is a very potent neurotoxin that, in very small doses, paralyzes the function of the facial muscles (or wherever it is injected).
In fact, a very interesting study was conducted that demonstrated that Botox affects emotions, or more precisely, our ability to experience them. The reason is quite simple: our brain regulates emotional responses based on different factors – and one of them is the movement of the facial muscles. If we cannot perform these movements because they are limited due to Botox, our brain loses a valuable source of feedback.
However, beyond the potential negative aspects associated with large doses of Botox, this cosmetic treatment has also proven useful in alleviating the symptoms of other conditions, such as migraines.
Now, a study conducted at the University of Basel has revealed a new effect of Botox: it helps combat depression. The research team states that paralyzing the area between the eyebrows significantly improves the symptoms of depression.
Botox for Depression
The study in question included 30 people suffering from major depression who did not respond to traditional antidepressants. Of these, 15 received a dose (five injections) of Botox, while the rest received a placebo (saline injections).
Six weeks after the Botox injections, the participants’ depressive symptoms were evaluated. The researchers found that those who received the Botox injections experienced a 47% reduction in depressive symptoms.
In contrast, in the placebo group, the reduction in symptoms only reached 9%. Most interestingly, this improvement remained stable throughout the 16-week study period.
How does Botox improve depressive symptoms?
Facial muscles play a deeper role than we usually think: they not only serve to communicate what we feel to others, but they also actively participate in how we experience our emotions.
When something makes us sad, that sadness manifests not only in our tone of voice, posture, or gait, but also in facial expressions such as frowning or tense lips. These signals don’t go unnoticed by our brain: upon seeing them, it interprets them as sadness and reinforces the emotion, creating a cycle that can perpetuate the negative feeling.
The explanation for this phenomenon lies in the theory of facial feedback, which maintains that facial expressions are not merely a reflection of what we feel, but rather contribute to generating and maintaining the emotion itself. Frowning in the face of a negative situation, for example, intensifies the feeling of sadness or anger, while smiling can amplify joy, even if the smile is voluntary. In the context of depression, this mechanism can become a constant reinforcement of negative emotions, making it difficult for the person to break the cycle of sadness.
This is where Botox comes in. This treatment temporarily blocks the muscles responsible for certain facial expressions, such as the corrugator supercilii, which is responsible for frowning. By preventing these muscles from contracting, Botox interrupts the feedback to the brain, partially breaking the cycle that reinforces sadness. As a result, depressive symptoms may decrease in intensity, not because the underlying emotional cause is directly addressed, but because the muscle signal that amplifies the negative emotion is reduced.
Obviously, Botox cannot eliminate depression entirely, nor is it a long-term cure, but it can be an alternative to traditional medications, followed by psychotherapy.
Sources:
American Society of Plastic Surgeons (2025) 2024 plastic surgery statistics report (ASPS procedural statistics release). American Society of Plastic Surgeons; 1-43.
Wollmer, M. A. et. Al. (2012) Facing depression with botulinum toxin: a randomized controlled trial. Journal of Psychiatric Research; 46 (5): 574-81.
Leave a Reply